Jiksak Bioengineering that holds a core technology producing Nerve Organoid with a three-dimensional structure similar to nerve in vivo by using microfluidic device announced an additional fundraising as total 170 million yen through allocation of new stocks to a third party. Jiksak Bioengineering is a venture company established in February 2017 by President Kawada who used work as a project researcher at Institute of Industrial Science, the University of Tokyo (IIS).
Since the company holds a core technology producing Nerve Organoid with a three-dimensional structure similar to nerve in vivo by using microfluidic device on the basis of the research results from IIS, it aims to produce Nerve Organoid as an experimental tissue model and also achieve the practical use of regenerative medicine with use of the Nerve Organoid.
The subscribers of new shares were ANRI (an independent venture capital company), Ohara Pharmaceutical Company group. The fundraising was regarded as Series A for Jiksak Bioengineering. President Kawada mentions, “It is planning to manufacture Nerve Organoid in both amyotrophic lateral sclerosis (ALS) model and healthy model as an experimental tissue model for screening ALS drugs in 2018 by using the fund”.
Related Reports and Monitors
Nanopore Sequencing 2019 – Patent Landscape Analysis
CRISPR Technology & Market Overview: from Lab to Industry 2018
Market & Technology